Safety and Anti-tumor Effects of Docetaxel Plus Cisplatin in Intermediate- and High-risk Endometrial Cancer

Endometrial cancer (EC) has a poor prognosis due to drug resistance. We evaluated the safety and efficacy of adjuvant combination chemotherapy with docetaxel plus cisplatin ((DP) docetaxel, 70 mg/m(2); cisplatin, 60 mg/m(2); every 28 days) in EC patients at intermediate-risk (IR) or high-risk (HR) f...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Anticancer research 2016-07, Vol.36 (7), p.3725
Hauptverfasser:	Miyahara, Daisuke, Katsuta, Takahiro, Maehara, Miyako, Takahashi, Yoko, Fukagawa, Satoshi, Miyata, Kouhei, Kiyoshima, Chihiro, Yotsumoto, Fusanori, Anan, Haruchika, Miyamoto, Shingo
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Carcinoma, Endometrioid - drug therapy Carcinoma, Endometrioid - mortality Cisplatin - administration & dosage Disease-Free Survival Drug Administration Schedule Endometrial Neoplasms - drug therapy Endometrial Neoplasms - mortality Female Humans Kaplan-Meier Estimate Middle Aged Proportional Hazards Models Retrospective Studies Risk Taxoids - administration & dosage Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!